300 results about "Cell model" patented technology

The invention discloses a method and a system for measuring an electrode constant of an oil conductivity valuing device, relates to the technical field of measurement, and breaks through the limitation of roughly taking an average value of an area of a polar plate traditionally by constructing an actual conductance cell model and defining parameter information, accurately deduces a conductance cell constant, and reversely calculates an effective relative area to determine the electrode constant. According to the method, the coaxial annular structure characteristics are attached, the influence of the edge effect and electric field line diffusion is avoided, and electrode constant calculation is more scientific and rigorous. Therefore, the accuracy of the constant value of the oil conductivity standard substance is guaranteed, a reliable reference is provided for verification and calibration of an oil conductivity meter, an effective oil conductivity measurement result is ensured, the electrostatic accident risk is reduced from the source, and the oil fuel quality and safety management and control are enhanced. The problems that an existing coaxial annular cylinder type electrode conductance cell is not strict in constant calculation and low in standard value credibility are effectively solved, and the electrode constant measurement accuracy of the oil conductivity valuing device is remarkably improved.

The invention discloses a combined evaluation method for in-vitro and in-vivo red fading and relieving effects of cosmetic raw materials, which comprises the following steps: in-vitro model evaluation: inducing a human immortalized umbilical vein endothelial cell model by adopting TNF-alpha, and detecting the secretion amount of a prostacyclin I2 factor to obtain a score of an in-vitro model; in-vivo model evaluation: adopting a chick embryo chorioallantoic membrane model, and obtaining a score of the in-vivo model according to the degree of vasoconstriction caused by the to-be-detected raw material sample acting on the chick embryo chorioallantoic membrane; and comprehensive evaluation: based on the score of the in-vitro model and the score of the in-vivo model, comprehensively evaluating the red fading and relieving efficacy of the raw material sample to be tested. According to the technical scheme, the defect that in the prior art, no cosmetic raw material soothing efficacy evaluation method for the vascular reactivity increasing mechanism exists is overcome, efficacy evaluation is more accurate, the method has the advantages of being comprehensive, short in test period, easy to operate, economical and convenient, and an effective reference basis is provided for screening and compounding schemes of red fading and soothing raw materials.

The invention provides an SNP (Single Nucleotide Polymorphism) marker for targeted identification of systemic lupus erythematosus of children and application of the SNP marker. A new SNP site (RS25671007) is identified in a child systemic lupus erythematosus patient through whole exon sequencing, the site is located at the 734th pair of basic groups of a PABPC3 gene, and mutation from C to T exists at the site, or mutation from threonine to isoleucine exists in coded amino acid. In addition, in-vitro cell model experiments prove that the SNP causes significant up-regulation of the antibody type transformation function, and the SNP can be used as a reference marker for risk stratification or medication guidance of early targeted diagnosis, detection, gene evaluation and the like of systemic lupus erythematosus of children.

This application discloses an artificial intelligence-based method, apparatus, device, and medium for 3D cell structure reconstruction, relating to the field of cell reconstruction. The method includes determining cross-modal fusion features using a multi-scale feature encoder based on point cloud data in the same coordinate system and pre-defined biological prior features, including local feature extraction, global feature extraction based on multi-head relative self-attention, and cross-modal feature fusion; performing dimensionality reduction using an improved local linear embedding manifold learning algorithm based on the cross-modal fusion features; determining topology-enhanced high-dimensional features using a graph convolutional network based on spatial proximity, feature similarity, and biological relevance, using point cloud data in the same coordinate system, pre-defined biological prior features, cross-modal fusion features, and low-dimensional features preserving topological relationships; and performing 3D reconstruction using a decoder based on the topology-enhanced high-dimensional features. This application can improve the accuracy and mechanistic interpretability of 3D cell models.

The invention discloses application of dikafen phenolic acid and ester derivatives thereof in preparation of medicines for treating pulmonary fibrosis. On an MRC-5 cell model induced by TGF-beta1, the bikafen phenolic acid and the multiple ester derivatives thereof show the activity of inhibiting alpha-SMA and COL1A1 protein expression; on a bleomycin-induced pulmonary fibrosis mouse model, the dimethyl ester derivative of the dikafen phenolic acid shows a good protective effect on experimental animals. Therefore, the dicafen phenolic acid and the ester derivative thereof have good application in the field of preparation of medicines for treating pulmonary fibrosis diseases.

This invention discloses a hepatocyte model with silencing or overexpression of LCMT1 and its construction method, comprising: passage and seeding cells in logarithmic growth phase into well plates; diluting plasmid siRNA1 or siRNA2 or an overexpression plasmid to an appropriate concentration, and then mixing it with transfection reagent dilution to obtain a transfection mixture; washing the cells in each well of the plate and adding another culture medium, then gently dripping the transfection mixture into the well plate, shaking well, and culturing in a cell culture incubator for a period of time; replacing the culture medium with complete culture medium without antibiotics to obtain the constructed hepatocyte model with silencing or overexpression of LCMT1. This invention, by constructing a hepatocyte model with silencing or overexpression of LCMT1 in the liver, allows for validation experiments to be conducted to study the development mechanism of liver fibrosis. It is suitable for widespread application in various laboratories and provides an experimental model basis for research on liver fibrosis and drug trials.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The invention belongs to the technical field of natural pharmaceutical chemistry, and particularly relates to a novel iridoid compound, namely, uncarcinin, separated from wingceltis, a pharmaceutically acceptable isomer of the novel iridoid compound, a wingceltis extract containing the novel iridoid compound, and a preparation method and application of the novel iridoid compound. The chemical structure of the utazonine is shown as a formula I, and the absolute configuration of the utazonine is (1S, 3S, 3aR, 4R, 7aS). The invention also provides a method for extracting the compound or the extract from the stem of the wingceltis, and purifying by combining pH gradient extraction with silica gel column chromatography, semi-preparative high performance liquid chromatography and gel chromatography to obtain the compound or the extract. The wingceltis cycline, the isomer of the wingceltis cycline, the wingceltis extract containing the wingceltis cycline or the pharmaceutical composition show remarkable gastric mucosa protection activity in an in-vitro cell model, particularly, the protection rate of the wingceltis cycline to ethanol-induced human gastric mucosa epithelial cell (GES-1) injury at the concentration of 50 mu M can reach 5.21%, and the wingceltis cycline, the isomer of the wingceltis cycline, the wingceltis extract containing the wingceltis cycline or the pharmaceutical composition show definite gastric mucosa protection activity.

The application provides a bispecific antibody conjugate drug targeting TF and Her2, and a preparation method and application thereof, and belongs to the technical field of biological drug preparation. The bispecific antibody provided by the application can target TF and / or Her2 antigens in tumor cells, has high stability, and has the advantages of easy expression, purification and conjugation. The bispecific antibody can specifically bind to tumor surface antigens and be internalized into tumor cells, and can specifically kill tumor cells. The bispecific antibody conjugate drug prepared based on the bispecific antibody has good tumor inhibition effect in a cell model and an animal model, is non-toxic and harmless to animals, and has excellent potential for treating cancer.

The invention discloses a human immortalized pure renal cyst cell line SRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human immortalized pure renal cyst cell line is named as SRC-X1, the cell line is preserved in the China Center for Type Culture Collection on September 19, 2025, and the preservation number is CCTCC NO: C2025303. The human immortalized pure renal cyst cell line SRC-X1 is applied to preparation, screening or evaluation of renal cyst treatment drugs. The invention also discloses the application of the human immortalized pure renal cyst cell line SRC-X1 as a renal cyst cell model. The human immortalized pure renal cyst cell line SRC-X1 is applied to renal cyst basic or clinical research as an experimental material.

The invention provides an indium tin oxide mechanical property simulation method and device and electronic equipment, and relates to the technical field of indium tin oxide simulation, and the indium tin oxide mechanical property simulation method comprises the following steps: carrying out proton irradiation simulation on an indium tin oxide material virtual model according to obtained proton environment parameters to obtain primary recoil atomic characteristic data; carrying out atom collision simulation according to the primary recoil atom characteristic data and the obtained cell expansion model of the indium tin oxide to obtain defect atom concentration; constructing a defect indium tin oxide model according to the defect atom concentration; and performing a tensile test on the defective indium tin oxide model to obtain defect stress-strain data. According to the method, the accuracy of mechanical property simulation of the indium tin oxide can be improved.

The application belongs to the technical field of biotechnology, and particularly relates to a human metapneumovirus mouse-adapted strain and application thereof. Compared with wild strains, the strain can exhibit stronger susceptibility to animals, and can cause typical clinical symptoms and even death. For example, after the strain infects BALB / c mice, the disease symptoms are obvious, 83% of the mice have a severe decrease in body weight to below 75% after infection, and have reached the humane killing standard. Four days after the strain infects BALB / c mice, the mortality rate is above 50%. The strain can be used to construct a cell model or an animal model of human metapneumovirus infection or a disease caused by the human metapneumovirus, and is further used to screen drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus. In addition, the strain can also be used to prepare drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus, and to prepare antibodies or antisera against the human metapneumovirus.

The invention discloses a bearing and wave-transmitting integrated design method and system for a variable-density honeycomb structure radome, and relates to the technical field of high-speed aircraft radome design. The method comprises the following steps: carrying out force / heat / electric performance characterization on a honeycomb cell element model; sensitivity analysis is conducted on the relation between the cell element structure parameters and the electromagnetic performance, and key design parameters are obtained; establishing an electrical performance calculation model of the two-dimensional honeycomb structure planar radome; determining an antenna-radome system, dispersing the three-dimensional radome in the axial direction to form a plurality of design points, and calculating a weighted average incident angle and force thermal load distribution of each design point; calculating an initial honeycomb relative density recommendation value at each design point; calculating the wave transmission rate and the aiming error of the formed variable-density radome; calculating the force thermal deformation and stress of the variable-density radome; and judging whether the scheme performance meets constraint conditions or not. By optimizing the distribution rule of the variable-density honeycomb structure, comprehensive optimization of the bearing performance and the wave-transparent performance of the radome is achieved.

This invention discloses an automatic inspection report generation and display method, including the following steps: Step 1: drawing a configuration screen according to requirements and selecting a database connection based on actual conditions; Step 2: configuring database request parameters and data processing parameters or functions for the cell model targeting data point objects; Step 3: querying real-time cross-section data or historical database data according to the parameters configured in the configuration screen; Step 4: updating the data results after calculation operations for the cell model in the configuration screen; Step 5: converting the configuration screen to generate a report file or database file. This invention provides a unified, universal, and feasible automated process for requesting and displaying data based on the drawing, configuration, data request, and report export functions of the configuration screen. It also utilizes server scripts to ensure the program can run effectively for a long time and is readily available with the server, and provides a downloadable inspection report function on the system interface front end.

The invention discloses a construction method of a coronary artery microcirculation disturbance cell model, and belongs to the technical field of biological medicine. According to the method, mouse heart microvascular endothelial cells (MCMEC) are taken as objects, tetrachlorohydroquinone (TCHQ) is used for treating for 6 hours at the concentration of 20-40 [mu] M, and CMD typical characteristics such as apoptosis, increase of reactive oxygen species (ROS), reduction of nitric oxide (NO) and release of inflammatory factors (TNF-alpha and IL-1beta) of the cells are induced. The TCHQ is applied to construction of the CMD model for the first time, and the model is stable, good in repeatability and capable of being used for CMD pathogenesis research and drug screening.

The invention provides a construction method of a non-small cell lung cancer histone H1.3 arginine methylation point mutation cell model. The construction method comprises the following steps: designing mutation primers H1.3 R80A-F and H1.3 R80A-R; the method comprises the following steps: by taking a pCDH-HA-H1.3-Flag plasmid as a template, carrying out PCR (Polymerase Chain Reaction) amplification by adopting a mutation primer, digesting a product by DMT enzyme, and converting a competent cell to obtain a mutant plasmid; and co-transfecting the mutant plasmid and a helper plasmid to a packaging cell, collecting a virus solution, filtering, infecting an A549 cell, adding Polybrene to assist infection, culturing, and screening a stably transfected cell strain by using puromycin to obtain the recombinant plasmid. The invention also provides application of the mutant cell model obtained by the construction method. According to the invention, the blank of histone H1.3 methylation research is filled, the 80th arginine is clear as a core modification site, and the established model provides a new tool for lung cancer mechanism research and drug research and development.

The invention provides a method for predicting the load performance of a corrosion inhibitor on a covalent organic framework material. The method is applied to the field of material simulation and design. The method comprises the following steps: determining the length of a target monomer connecting chain in various covalent organic framework material structures in a chain length increasing manner, and constructing covalent organic framework material unit cell models of various corresponding different topological structures based on the length of the target monomer connecting chain; performing structure optimization on the covalent organic framework material unit cell model and the molecular models of the various corrosion inhibitors to obtain an optimized covalent organic framework material unit cell model and an optimized molecular model; determining adsorption energy, electronic structure change and electronic interaction of molecular models of different optimized corrosion inhibitors on each optimized covalent organic framework material unit cell model; based on adsorption energy, electron structure change and electron interaction, the load performance of different corrosion inhibitors on the covalent organic framework material is predicted.

The invention discloses a dual-channel fluorescent probe for simultaneously detecting nitric oxide and cysteine as well as a preparation method and application of the dual-channel fluorescent probe. The structural formula of the dual-channel fluorescent probe is shown in the specification. The invention also specifically discloses a preparation method of the dual-channel fluorescent probe and application of the dual-channel fluorescent probe in selective detection of NO and Cys, dynamic visual detection of NO and Cys in a biological cell system and in ferroptosis and depression cell models. The dual-channel fluorescent probe disclosed by the invention has the advantages of strong specificity, good selectivity, no spectrum crosstalk and the like.

This invention belongs to the field of biotechnology, specifically relating to a broad-spectrum neutralizing antibody against porcine epidemic diarrhea virus (PEDV) and its applications. This invention screened a broad-spectrum neutralizing antibody against PEDV, 6G2. Cell model evaluation revealed that the antibody effectively blocked infection of cells by several highly prevalent PEDV genotypes: G1a, G1b, G2a, G2b, G2c, and S-INDEL. Further animal infection experiments in pigs demonstrated that the neutralizing antibody provided by this invention has good preventive and therapeutic effects against PEDV, which is of great significance for improving the ability of pig farms to control PEDV.

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

The invention discloses a photovoltaic model parameter identification method, device and system, and a storage medium, and the method comprises the steps: obtaining the output voltage and output current experiment data of a photovoltaic model under preset temperature and illumination conditions, and constructing a target function of photovoltaic model parameter identification; the target function comprises to-be-identified parameters; and optimizing the objective function by using an improved optimization algorithm to identify parameter values of the photovoltaic model parameters. By the adoption of the technical scheme, the defects that in the prior art, local optimum is prone to occurring, and the recognition effect is unstable are effectively overcome, and the recognition precision of the photovoltaic cell model parameters is improved.

This invention belongs to the field of biochemistry, specifically relating to the preparation and application of a cyclic peptide. The structure of the cyclic peptide CYP9 is Lys-Gly-Val-dGlu-Gly-Pro-Asp-CONH2, wherein lysine at position 1 and aspartic acid at position 7 are cyclically linked by an amide bond. This invention investigates the biological activity of the cyclic peptide CYP9, including constructing in vitro cell models and in vivo animal models of pulmonary fibrosis to evaluate its in vitro antifibrotic activity and in vivo therapeutic effects, as well as studying its cytotoxicity, serum stability, and pharmacokinetics. The results show that, compared with the parent peptide YD, the cyclic peptide CYP9 obtained in this invention exhibits superior activity and stability in all aspects, and can be used to prepare drugs for the prevention of pulmonary fibrosis.

The invention discloses white paeony root polysaccharide with a blood fat reducing function as well as a preparation method and application of the white paeony root polysaccharide. The radix paeoniae alba polysaccharide with the blood fat reducing function is extracted from radix paeoniae alba for the first time, and cell experiments prove that the polysaccharide has the effect of reducing lipid generation in a high-fat cell model; further animal model experiments prove that the polysaccharide can also achieve the blood fat reducing effect in a hyperlipidemia animal model, it is proved that the polysaccharide can be used for preparing the blood fat reducing medicine, and the polysaccharide belongs to natural ingredients and is high in safety and wide in application prospect.

The invention provides a nucleic acid construct which comprises an immune response regulatory sequence and a coding sequence of a reporter gene driven by a promoter sequence, and the immune response regulatory sequence comprises a transcription factor binding regulatory element RE which is co-stimulated and regulated by transcription factors AP-1 and CD28. The invention also provides an in-vitro immune effector function reporter gene cell model containing the nucleic acid construct, and the cell model can realize effector function activity determination performance of sensitive and potent signals so as to evaluate ADCC and ADCP killing action mechanisms and titers mediated by antibody-dependent disease cells designed by an Fc structural domain of a therapeutic antibody product. In addition, the immunosuppression and regulation efficacy of a targeted CTLA-4 or Abatacept mediated treatment method on a CD28 co-activation pathway can be evaluated.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of MIGA2 serving as a target spot in screening or preparing a medicine for treating colorectal cancer. According to the invention, the correlation between MIGA2 and colorectal cancer progress is analyzed through large-queue bioinformatics; the influence of MIGA2 on the proliferation, migration and invasion ability of colorectal cancer cells is analyzed from an in-vitro cell model; analyzing a key molecular mechanism of MIGA2 playing a cancer inhibition function; the influence of MIGA2 on colorectal cancer tumor growth is analyzed in an in-vivo mouse model, the influence of MIGA2 mediated mitochondrial-endoplasmic reticulum contact on colorectal cancer tumor growth is analyzed, and it is verified in multiple dimensions that MIGA2 can become an effective treatment target of colorectal cancer.

The application provides an organ chip, which comprises, from top to bottom, a liquid collecting layer (1), a pressing layer (2), a glue injection layer (3), a tissue layer (4), a film layer (5) and an oxygen control layer (6). The application provides a novel organ chip, which comprises a film layer and an oxygen control layer, is used for making oxygen pass through the film layer and be eliminated by an oxygen absorbent in the oxygen control layer, liquid cannot pass through the film layer, so that the liquid circulates or is supplemented in the microfluidic channel, and the oxygen concentration in the culture solution is made to be closer to the real physiological environment in the human body based on the cavity and the through structure formed by laminating and sealing of the layers. In addition, a plurality of molds are arranged, so that a plurality of cell models can be simultaneously cultured, and a high-throughput culture effect is realized.

The invention relates to the technical field of cell biology, and particularly discloses an isolated culture method of primary meibomian gland epithelial cells, the obtained primary meibomian gland epithelial cells and application of the primary meibomian gland epithelial cells. The method comprises the following steps: efficiently and mildly digesting meibomian gland tissues by adopting a compound digestive juice consisting of I-type collagenase, dispersing enzyme and trypsin in a specific ratio; stopping digestion by using a serum-containing neutralizing solution and collecting cells; the method comprises the following steps: promoting cell attachment by using a serum-containing initial culture medium, and carrying out selective amplification by using a serum-free proliferation culture medium to finally obtain high-purity and high-activity primary meibomian gland epithelial cells. The method solves the problems of long digestion time, low cell yield, poor purity and the like in the traditional method. The obtained cell can be used for constructing a meibomian gland dysfunction model, screening drugs and researching lipid metabolism, and an important technical platform and a cell model are provided for research and treatment of related eye diseases.

The invention discloses application of 20-Deacetyltaxupine X in preparation of a medicine for preventing and / or treating amyotrophic lateral sclerosis, and belongs to the technical field of medicinal chemistry. The novel serine-threonine kinase CDC7 inhibitor and CDC7 form a new hydrogen bond, and guidance is provided for design of CDC7 inhibitor drugs. The novel serine-threonine kinase CDC7 inhibitor has a protection effect on an amyotrophic lateral sclerosis cell model, and can be used as an amyotrophic lateral sclerosis resisting medicine. The novel serine-threonine kinase CDC7 inhibitor has a protective effect by inhibiting apoptosis of an amyotrophic lateral sclerotic cell model.

The invention relates to the technical field of battery heat management, and discloses a battery heating film power distribution optimization method and device and electronic equipment, and the method comprises the steps: calculating the total power of a heating film according to the specific heat capacity, mass and average heating rate of a battery cell; performing gridding multi-region division on the heating film by combining a battery cell module temperature field, and averagely distributing the total power to obtain the initial power of each region; performing optimization based on the difference between the initial simulation / actual measurement temperature of each region and the target temperature to obtain a first gradient optimization power; performing optimization in combination with the temperature after the first optimization and a preset temperature compensation coefficient to obtain a second gradient optimization power; and calculating the temperature range of each area during heating and heat preservation, judging whether the temperature range is smaller than a preset threshold, if so, outputting final power distribution, and otherwise, returning to the second gradient iterative optimization. The heating temperature difference of the battery module can be controlled within the preset threshold value, different battery cell models and module arrangement modes are adapted, the research and development verification period is greatly shortened, and the performance and the service life of the battery are guaranteed.